［1］HELLMANN M,NATHANSON T,RIZVI H,et al.Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer［J］.Cancer Cell,2018,33(5):843-852.e4.
［2］YOSHINO H,YAMADA Y,ENOKIDA H,et al.Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma［J］.PLoS One,2020,15(7):e0236119.
［3］CHEN W,YANG W,CHEN P,et al.Disulfiram copper nanoparticles prepared with a stabilized metal Ion ligand complex method for treating drug-resistant prostate cancers［J］.ACS Applied Materials & Interfaces,2018,10(48):41118-41128.
［4］LUN X,WELLS J,GRINSHTEIN N,et al.Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma［J］.Clinical Cancer Research,2016,22(15):3860-3875.
［5］SKROTT Z,MISTRIK M,ANDERSEN KK,et al.Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4［J］.Nature,2017,552(7684):194-199.
［6］BRüNING A,KAST R.Oxidizing to death:disulfiram for cancer cell killing［J］.Cell Cycle (Georgetown,Tex),2014,13(10):1513-1514.
［7］WANG Z,TAN J,MCCONVILLE C,et al.Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells［J］.Nanomedicine:Nanotechnology,Biology,and Medicine,2017,13(2):641-657.
［8］KITA Y,HAMADA A,SAITO R,et al.Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer:a summary of preclinical studies［J］.British Journal of Cancer,2019,121(12):1027-1038.
［9］SKROTT Z,MAJERA D,GURSKY J,et al.Disulfiram's anti-cancer activity reflects targeting NPL4,not inhibition of aldehyde dehydrogenase［J］.Oncogene,2019,38(40):6711-6722.
［10］MULLARKY E,LUCKI N,BEHESHTI ZAVAREH R,et al.Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers［J］.Proceedings of the National Academy of Sciences of the United States of America,2016,113(7):1778-1783.
［11］LOCASALE J,GRASSIAN A,MELMAN T,et al.Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis［J］.Nature Genetics,2011,43(9):869-874.
［12］SAMANTA D,PARK Y,ANDRABI S,et al.PHGDH expression is required for mitochondrial redox homeostasis,breast cancer stem cell maintenance,and lung metastasis［J］.Cancer Research,2016,76(15):4430-4442.
［13］SPILLIER Q,VERTOMMEN D,RAVEZ S,et al.Anti-alcohol abuse drug disulfiram inhibits human PHGDH via disruption of its active tetrameric form through a specific cysteine oxidation［J］.Scientific Reports,2019,9(1):4737.
［14］PAN M,ZHENG QY,YU YY,et al.Seesaw conformations of Npl4 in the human p97 complex and the inhibitory mechanism of a disulfiram derivative［J］.Nature Communications,2021,12(1):41118-41128.
［15］LAFFIN B,PETRASH J.Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in human cancers［J］.Frontiers in Pharmacology,2012,3:104.
［16］PENNING T.The aldo-keto reductases (AKRs):Overview［J］.Chemico-Biological Interactions,2015,234:236-246.
［17］JIN Y,PENNING T.Aldo-keto reductases and bioactivation/detoxication［J］.Annual Review of Pharmacology and Toxicology,2007,47:263-292.
［18］ZHOU Y,HUANG F,YANG Y,et al.Paraptosis-inducing nanomedicine overcomes cancer drug resistance for a potent cancer therapy［J］.Small (Weinheim an der Bergstrasse,Germany),2018,14(7):1702446.
［19］CHEN X,ZHANG X,CHEN J,et al.Hinokitiol copper complex inhibits proteasomal deubiquitination and induces paraptosis-like cell death in human cancer cells［J］.European Journal of Pharmacology,2017,815:147-155.
［20］BARILLI A,ATZERI C,BASSANETTI I,et al.Oxidative stress induced by copper and iron complexes with 8-hydroxyquinoline derivatives causes paraptotic death of HeLa cancer cells［J］.Molecular Pharmaceutics,2014,11(4):1151-1163.
［21］SUN T,YANG W,TOPRANI SNEH M,et al.Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram［J］.Cell Communication and Signaling:CCS,2020,18(1):36.
［22］ILJIN K,KETOLA K,VAINIO P,et al.High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth［J］.Clin Cancer Res,2009,15(19):6070-6078.
［23］LIN J,HAFFNER MC,ZHANG Y,et al.Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth［J］.Prostate,2011,71(4):333-343.
［24］KETOLA K,KALLIONIEMI O,ILJIN K.Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells［J］.PLoS One,2012,7(12):e51470.
［25］SCHWEIZER M,LIN J,BLACKFORD A,et al.Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer［J］.Prostate Cancer and Prostatic Diseases,2013,16(4):357-361.
［26］THOMA C.Prostate cancer:copper unlocks therapeutic potential of disulfiram［J］.Nat Rev Urol,2014,11(12):664.
［27］SAFI R,NELSON ER,CHITNENI SK,et al.Copper signaling axis as a target for prostate cancer therapeutics［J］.Cancer Res,2014,74(20):5819-5831.
［28］SHARMA V,VERMA V,LAL N,et al.Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor beta［J］.Mol Carcinog,2016,55(11):1843-1857.
［29］MAJERA D,SKROTT Z,BOUCHAL J,et al.Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors,vorinostat and disulfiram［J］.The Prostate,2019,79(4):352-362.
［30］TAWARI PE,WANG ZP,NAJLAH M.The cytotoxic mechanisms of disulfiram and copper (II) in cancer cells［J］.Toxicol Res (Camb),2015,4(6):1439-1442.
［31］POLESZCZUK J,HAHNFELDT P,ENDERLING H.Evolution and phenotypic selection of cancer stem cells［J］.PLoS Computational Biology,2015,11(3):e1004025.
［32］KRESO A,DICK J.Evolution of the cancer stem cell model［J］.Cell Stem Cell,2014,14(3):275-291.
［33］张钢,林毅枢,王强.ALDH1在膀胱癌组织中的表达及与临床特征的相关性分析［J］.癌症进展,2018,16(02):183-185.
ZHANG G,LIN YS,WANG Q.Expression of ALDH1 in bladder cancer and its correlation with clinical features［J］.Oncology Progresa,2018,16(02):183-185.
［34］YANG Z,GUO F,ANDREAS E.Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines［J］.Biomedicine & Pharmacotherapy,2019,113:108727.
［35］GENG H,GUO W,FENG L.Diallyl trisulfide inhibited tobacco smoke-mediated bladder EMT and cancer stem cell marker expression via the NF-κB pathway in vivo［J］.J Int Med Res,2021,49(3):300060521992900.
［36］YU HY,TANG ZH,ZHANG DW,et al.Pharmacokinetics,biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy［J］.Journal of Controlled Release,2015,205:89-97.
［37］SONG W,TANG Z,SHEN N,et al.Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance［J］.J Control Release,2016,231:94-102.
［38］DUSANA MAJERA,ZDENEK SKROTT,KATARINA CHROMA,et al.Targeting the NPL4 adaptor of p97/VCP segregase by disulfiram as an emerging cancer vulnerability evokes replication stress and DNA damage while silencing the ATR pathway［J］.Cells,2020,9(2):469.
［39］YOSHINO H,NOHATA N,MIYAMOTO K,et al.PHGDH as a key enzyme for serine biosynthesis in HIF2α-targeting therapy for renal cell carcinoma［J］.Cancer Research,2017,77(22):6321-6329.
［40］ZHENG P,LIU CZ,WU YQ,et al.Quantitative proteomics analysis reveals novel insights into mechanisms of action of disulfiram (DSF)［J］.Proteomics,Clinical Applications,2021:e2100031.
［41］CHAMOTO K,HATAE R,HONJO T.Current issues and perspectives in PD-1 blockade cancer immunotherapy［J］.International Journal of Clinical Oncology,2020,25(5):790-800.
［42］ZHA J,BI SL,DENG MM,et al.Disulfiram/copper shows potent cytotoxic effects on myelodysplastic syndromes via inducing Bip-mediated apoptosis and suppressing autophagy［J］.European Journal of Pharmacology,2021,902:174107.
［43］MO L,ZHENG XY,HUANG HY,et al.Hyperactivation of Ha-ras oncogene,but not Ink4a/Arf deficiency,triggers bladder tumorigenesis［J］.The Journal of Clinical Investigation,2007,117(2):314-325.